New Alliance Capital is a venture capital and private equity firm founded in 2008 and headquartered in Shanghai, China. The firm specializes in early-stage, growth-stage, and pre-IPO investments across a diverse range of sectors, including high-end manufacturing, technology, advanced agriculture, consumer goods, information, media, energy, recycling, environmental protection, and modern services. New Alliance typically invests amounts ranging from approximately $4.71 million to $31.41 million. In addition to its investments in China, the firm also focuses on private equity opportunities in the United States, particularly in the technology, media, and telecommunications (TMT), cultural media, healthcare, and energy sectors.
Beijing Advaccine Biotechnology Co., Ltd. engages in discovery of new vaccines, both preventive and therapeutic. The company product pipeline consists respiratory syncytial virus (RSV) vaccine, type1 diabetes( T1D) therapeutic vaccine, and hepatitis B virus (HBV) therapeutic vaccine. Its vaccines help in inducing immuno-tolerance and T-cell stimulation for certain diseases. The company is based in Beijing, China.
CapitalBio Technology Co., Ltd. is a life science company based in Beijing, China, specializing in the development and commercialization of healthcare solutions. Founded in 2012, it offers a wide range of products including nucleic acid detection kits for respiratory pathogens and Hepatitis B virus, as well as a Thalassemia gene mutations detection kit. The company also provides microarray and microfluidic chips, along with related instruments, software, reagents, and consumables for various applications such as clinical diagnostics, drug development, and molecular breeding. Additionally, CapitalBio Technology offers services including SNP analysis, mRNA expression profiling, DNA methylation detection, and sequencing. As a subsidiary of CapitalBio Corporation, the company is equipped with over 35,000 square meters of office space and employs more than 500 staff members, the majority of whom hold advanced degrees.
Beijing Advaccine Biotechnology Co., Ltd. engages in discovery of new vaccines, both preventive and therapeutic. The company product pipeline consists respiratory syncytial virus (RSV) vaccine, type1 diabetes( T1D) therapeutic vaccine, and hepatitis B virus (HBV) therapeutic vaccine. Its vaccines help in inducing immuno-tolerance and T-cell stimulation for certain diseases. The company is based in Beijing, China.
CooTek (NYSE: CTK), founded in 2008, listed on NYSE on September 28th, 2018, is a global and fast-growing mobile internet company that develops innovative mobile apps and artificial intelligence technology. With a massive global user base, CooTek aims to empower users to express themselves and enjoy relevant content seamlessly. CooTek’s flagship mobile app, TouchPal Keyboard, uses unparalleled technology to provide the best input experience to both Android and iPhone users. CooTek has also developed many content-rich apps, spanning across 5 selected verticals including fitness, lifestyle, healthcare, news and short videos, and entertainment. In September 2018, CooTek’s global products reached an average of 213.7 million monthly active users around the world. Headquartered in Shanghai, CooTek offices can be found in Silicon Valley, Beijing, Taipei, Guangzhou, and Shenzhen. Today, CooTek has over 170 patent applications and granted patents worldwide and continually pursue excellence in technology innovation and intellectual property development. CooTek has also established its own big data development center and AI lab in Silicon Valley. Many academic papers written by CooTek have been used in discussions at world-renowned big data and AI conferences such as AAAI, KDD and CIKM.